Looking ahead in retinal disease management: highlights of the 2019 angiogenesis, exudation and degeneration symposium
- PMID: 31161069
- PMCID: PMC6542006
- DOI: 10.1186/s40942-019-0174-y
Looking ahead in retinal disease management: highlights of the 2019 angiogenesis, exudation and degeneration symposium
Conflict of interest statement
Competing interestsCP: none CW: Research Support: Adverum, Aerpio, Allergan, Apellis, Clearside, Genentech, Neurotech, Novartis, Ophthotech, Opthea, Regeneron, Regenxbio, Roche, Samsung, Santen. Consulting: Alimera Sciences, Adverum, Aerpio, Allegro, Allergan, Apellis, Bayer, Clearside, D.O.R.C., EyePoint, Genentech, Kodiak, Notal Vision, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Regeneron, Regenxbio, Roche, Santen. Speakers Bureau: Regeneron.
References
-
- World Helath Organization (WHO). Global report on diabetes. 2016. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?.... Accessed 26 Apr 2019.
LinkOut - more resources
Full Text Sources
